ANTI-DEPRESSANT DRUG SEROXAT

Motion Text

That this House calls for the anti-depressant drug Seroxat to be withdrawn from use for new prescribing pending an urgent, fully independent review of its and other SSRI anti-depressants' safety, because of the extensive evidence of severe withdrawal reactions and an increased risk of suicide associated with it; and calls on the Medicines and Healthcare Products Regulation Agency in conducting the review to include people with experience of using Seroxat and to make full use of the consumer-based evidence and research available, such as that conducted by Panorama and Mind.